{
  "id": 2889473,
  "title": "Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?",
  "url": "https://urgent.news/2026/08/23/medtronic-vs-thermo-fisher-which-healthcare-turnaround-offers-more",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-23T22:53:40.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/medtronic-vs-thermo-fisher-healthcare-225340177.html"
  },
  "original_language": "en",
  "account": "Medtronic and Thermo Fisher Scientific are two healthcare firms currently undergoing recoveries, but the forces driving each company's turnaround are markedly different. For Medtronic, the turnaround is largely a result of internal execution, product innovation, and strategic investments in high-growth segments. Thermo Fisher, on the other hand, is relying on improving customer spending across the broader life sciences industry.\n\nMedtronic's recent results show that its turnaround is beginning to yield measurable financial performance. The company reported its highest annual revenue growth in a decade, with particular strength coming from its cardiac segment, which saw a 78% global revenue increase and 124% growth in the U.S. Additionally, several of Medtronic's newer product launches are contributing meaningfully to growth and strengthening its competitive position in high-growth markets.\n\nIn contrast, Thermo Fisher's recovery is contingent on an overall improvement in demand across its life sciences businesses. The company highlighted improving customer activity in pharmaceutical and biotechnology markets, as well as the return to growth in its Analytical Instruments business, which had faced weak demand for nearly two years. However, even this improvement represents a modest 5% increase in organic revenue, which is still below the double-digit growth rates the company experienced previously.\n\nInvestors must consider the drivers of each company's recovery when assessing their potential upside. Medtronic's turnaround appears to be more resilient, as it is driven by internal innovation and product development. However, Thermo Fisher's recovery could benefit from sustained improvements in the broader life sciences industry, potentially offering greater operating leverage if customer spending continues to recover.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}